Advancing T‑Cell Engagers Targeting Driver Mutations for Solid Tumors
- Discovery and engineering approaches for generating highly selective pHLA-targeted binders.
- Preclinical evaluation strategies, including functional activity, specificity, and safety assessment.
- Key learnings from advancing pHLA-targeted therapies from nonclinical development into the clinic, and implications for next-generation programs